RA
MRSN

Royce & Associates’s Mersana Therapeutics MRSN Stock Holding History

Royce & Associates’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17
Closed -$7K – 1241
2018
Q1 		$7K Buy
17
+3
+21% +$1.19K ﹤0.01% 1225
2017
Q4 		$6K Buy
+14
New +$6.11K ﹤0.01% 1229

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Royce & Associates's MRSN Position: Q2 2018 in Review

Royce & Associates sold out of Mersana Therapeutics (MRSN) in Q2 2018, closing a stake of 17 shares — an estimated $7K sold.

Royce & Associates first reported a position in MRSN in Q4 2017 and held it in 2 quarters. The position peaked at $7K in Q1 2018. 53 funds tracked by Wall St. Rank hold MRSN as of Q2 2018.

  • Royce & Associates reported no remaining Mersana Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Royce & Associates sold 17 Mersana Therapeutics shares in Q2 2018, an estimated $7K.
  • Royce & Associates first reported a position in Mersana Therapeutics in Q4 2017 and held it in 2 quarters.
  • Royce & Associates's Mersana Therapeutics position peaked at $7K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.